UK Independent Finance Intelligence · Est. 2024
Updated daily Newsletter For business
Home Hub: Insurance Travel Insurance for Crohn's Disease UK 2026: Declaration, Cover and Finding the Right Policy
Hub: Insurance

Travel Insurance for Crohn's Disease UK 2026: Declaration, Cover and Finding the Right Policy

CT
Chandraketu Tripathi
Finance Editor, Kaeltripton
Published 11 May 2026
Last reviewed 11 May 2026
✓ Fact-checked
Travel Insurance for Crohn's Disease UK 2026: Declaration, Cover and Finding the Right Policy

Photo by Vitaly Gariev on Unsplash

Advertisement

TL;DR: Crohn's disease is a pre-existing condition that must be declared on UK travel insurance applications. Cover depends on disease activity, treatment complexity, and surgical history. Stable, well-managed Crohn's may attract full cover or a modest loading; complex, recently active disease is more likely to result in an exclusion or specialist referral. MoneyHelper's travel insurance directory is the primary resource for those declined by mainstream providers.

KEY FACTS
  • Crohn's disease is classified as a pre-existing medical condition and must be declared when applying for travel insurance in the UK, regardless of current disease activity (abi.org.uk).
  • The Consumer Insurance (Disclosure and Representations) Act 2012 makes it a legal requirement for consumers to answer insurer medical screening questions with reasonable care and accuracy (legislation.gov.uk).
  • MoneyHelper's specialist travel insurance directory provides a list of FCA-regulated providers experienced in covering inflammatory bowel conditions including Crohn's (moneyhelper.org.uk).
  • The FCA requires regulated insurers that cannot accommodate a consumer's pre-existing condition to direct them to the MoneyHelper specialist provider directory (fca.org.uk).
  • UK residents travelling within the EEA can use a UK GHIC (nhsbsa.nhs.uk) for access to state healthcare at the local rate, but this does not replace travel insurance or cover all costs associated with Crohn's-related emergency treatment abroad.

How UK Travel Insurers Assess Crohn's Disease

Crohn's disease is a chronic inflammatory bowel condition that can affect any part of the gastrointestinal tract. It is characterised by periods of remission and relapse, and its severity ranges from mild, managed symptoms to severe complications requiring surgery. For travel insurance purposes, Crohn's disease is considered a pre-existing condition by UK insurers, meaning it must be disclosed on any medical screening questionnaire that asks about gastrointestinal, inflammatory, or ongoing medical conditions. The Association of British Insurers' guidance on pre-existing conditions confirms that inflammatory bowel disease falls into this category (abi.org.uk). Insurers assess Crohn's disease with reference to several key risk factors. Disease location (small bowel, large bowel, or both) matters, as does whether the person has experienced complications such as fistulae, strictures, or abscesses. The treatment regimen is scrutinised closely: a person managed with a single maintenance drug presents a different risk profile than one on combination immunosuppression or biological therapy. Surgical history is also significant - previous bowel resections, formation of a stoma, or ongoing post-surgical complications will affect the underwriting outcome. The FCA requires that insurers apply clear, specific questions and fair assessment processes (fca.org.uk).

What to Declare and How to Complete Medical Screening Accurately

Accurate and complete disclosure is the foundation of a valid travel insurance policy for anyone with Crohn's disease. The Consumer Insurance (Disclosure and Representations) Act 2012 requires consumers to take reasonable care in answering insurer questions, and misrepresentation - even if unintentional - can give the insurer grounds to reduce or reject a claim (legislation.gov.uk). When completing a travel insurance medical screening for Crohn's disease, consumers should be prepared to provide the date of diagnosis, the date of the last symptomatic episode or hospitalisation, the current medication regime including all drug names and doses, and details of any surgical procedures. If the condition is being described as "stable" or "in remission," it is advisable to confirm this with a treating GP or gastroenterologist before making that declaration, as clinical stability has a specific meaning that may differ from the absence of symptoms in day-to-day life. Where the screening questions do not allow for the level of detail needed to accurately represent a complex case, telephone-based medical screening - which some specialist insurers offer - can provide a more appropriate format. MoneyHelper advises that applicants should keep a record of all screening submissions and confirmations, as these may be relevant in the event of a claim dispute (moneyhelper.org.uk).

Cover Outcomes: Full Cover, Exclusions, and Declined Applications

After declaring Crohn's disease, the underwriting outcome typically falls into one of three categories. Where the condition has been stable for a sustained period, is managed on a straightforward therapy, and has not required recent hospitalisation or surgery, some insurers will offer full cover including for Crohn's-related emergencies abroad. This is the most favourable outcome but is not guaranteed even for mild presentations, as it depends on the individual insurer's underwriting appetite. More commonly, insurers will accept an application but apply a specific exclusion for claims arising from or related to Crohn's disease. This means that if a flare-up, bowel obstruction, or other Crohn's-related complication occurs abroad, the associated medical costs would not be covered. The remainder of the policy - covering unrelated medical emergencies, trip cancellation for unrelated reasons, baggage, and so on - would remain valid. Where the condition is severe, active, or involves complex treatment such as biological therapy, mainstream insurers may decline to offer a policy at all. In this case, the FCA requires the insurer to direct the consumer to the MoneyHelper specialist directory (fca.org.uk). It is also worth checking whether a policy's exclusion wording is limited to Crohn's disease specifically or extends more broadly to inflammatory bowel disease or any gastrointestinal condition, as the latter is considerably more restrictive.

Specialist Travel Insurance for Crohn's Disease

Consumers who receive an exclusion or a declined application from mainstream insurers should approach specialist medical travel insurance providers. These firms are specifically structured to assess complex chronic conditions including Crohn's disease, ulcerative colitis, and related IBD conditions, and they typically apply more granular criteria than standard online comparison tools. The MoneyHelper travel insurance directory at moneyhelper.org.uk/en/everyday-money/insurance/travel-insurance-directory is the primary, FCA-endorsed route to accessing these providers. Applicants may be asked to submit a medical questionnaire in greater detail than standard screening, and in some cases providers may request a GP or consultant summary. Premiums at specialist providers are likely to be higher than those available through standard aggregators, but the coverage offered is more likely to include Crohn's-related emergencies and is less likely to generate a disputed claim. Annual multi-trip policies are available from some specialist providers, which can offer value for those who travel regularly. Consumers managing Crohn's disease with infliximab, adalimumab, or other biological therapies should confirm with any potential insurer whether emergency administration or related treatment abroad would be covered under the medical emergency section of a policy.

Travelling Safely with Crohn's Disease: Practical Steps

Preparation before travel is as important as securing the right insurance. The FCDO publishes travel advice for every destination at gov.uk/foreign-travel-advice, covering local healthcare standards and entry requirements. Travellers to EEA countries should apply for a UK GHIC at nhsbsa.nhs.uk before departure, which provides access to state healthcare at the local rate but does not cover all costs, repatriation, or private medical care. Medication management is critical for Crohn's disease: travellers should carry sufficient medication for the full trip duration plus additional days, and biological therapy users should liaise with their clinical team well in advance regarding storage, administration, and any required documentation for customs. A GP or consultant letter summarising the diagnosis, current treatment, emergency contacts, and relevant drug information - ideally in both English and the language of the destination - can significantly aid overseas medical teams in providing appropriate care quickly. Travellers should also have the contact number for their insurer's 24-hour medical emergency assistance line saved before departure, and should contact the line immediately in the event of any symptoms that could indicate a flare, rather than waiting to see whether the situation resolves. The Financial Ombudsman Service at financial-ombudsman.org.uk can assist if a claim is subsequently disputed (financial-ombudsman.org.uk).

Editorial Disclaimer: Kaeltripton.com is an independent editorial publisher and is not authorised or regulated by the Financial Conduct Authority. Content is for informational purposes only and does not constitute financial, investment, tax, legal or regulatory advice. Always verify rates and product details with the relevant provider, the FCA register, HMRC or the Bank of England before any financial decision.

Frequently Asked Questions

Do I have to declare Crohn's disease if it is in remission?

Yes. The Consumer Insurance (Disclosure and Representations) Act 2012 requires consumers to answer insurers' screening questions accurately and with reasonable care. If an insurer asks about inflammatory bowel disease or gastrointestinal conditions, Crohn's must be declared regardless of whether it is currently in remission (legislation.gov.uk).

I am on a biological therapy for Crohn's - will this affect my ability to get cover?

It is likely to affect the underwriting assessment. Biological therapies are associated with more complex disease profiles, which some mainstream insurers may not be equipped to assess. Specialist providers listed on the MoneyHelper travel insurance directory are more likely to offer appropriate cover for those on immunosuppressant or biological treatment regimens (moneyhelper.org.uk).

Yes, travel insurance is available following Crohn's-related surgery, though it will need to be declared in full. The type of surgery, the date it was performed, and the current post-operative status will all be assessed. Specialist insurers are generally better placed than mainstream providers to cover post-surgical IBD profiles.

What is the difference between the GHIC and travel insurance for someone with Crohn's disease?

The UK GHIC provides access to state healthcare in EEA countries at the local rate, but it does not cover all medical costs, does not cover repatriation to the UK, and may not cover private hospital care. For someone with Crohn's disease who could require emergency hospitalisation abroad, a comprehensive travel insurance policy that includes the condition is essential alongside the GHIC (nhsbsa.nhs.uk).

What should I do if a travel insurer refuses to cover my Crohn's disease?

Under FCA rules, a regulated insurer that cannot offer suitable cover must signpost the consumer to the MoneyHelper specialist travel insurance directory at moneyhelper.org.uk. If a claim is later rejected and the consumer believes this was unfair, a complaint can be made to the Financial Ombudsman Service at financial-ombudsman.org.uk, whose decisions are binding on regulated firms (fca.org.uk).

How We Verified This Guide

This guide was researched against primary UK regulatory sources including the Association of British Insurers (abi.org.uk), the Financial Conduct Authority (fca.org.uk), MoneyHelper (moneyhelper.org.uk), legislation.gov.uk, NHS Business Services Authority (nhsbsa.nhs.uk), and the Financial Ombudsman Service (financial-ombudsman.org.uk). Last reviewed May 2026 by Chandraketu Tripathi, finance editor at Kaeltripton.

Sources

Advertisement

Editorial Disclaimer

The content on Kaeltripton.com is for informational and educational purposes only and does not constitute financial, investment, tax, legal or regulatory advice. Kaeltripton.com is not authorised or regulated by the Financial Conduct Authority (FCA) and is not a financial adviser, mortgage broker, insurance intermediary or investment firm. Nothing on this site should be construed as a personal recommendation. Rates, figures and product details are indicative only, subject to change without notice, and should always be verified directly with the relevant provider, HMRC, the FCA register, the Bank of England, Ofgem or other appropriate authority before any financial decision is made. Past performance is not a reliable indicator of future results. If you require regulated financial advice, please consult a qualified adviser authorised by the FCA.

CT
Chandraketu Tripathi
Finance Editor · Kaeltripton.com
Chandraketu (CK) Tripathi, founder and lead editor of Kael Tripton. 22 years in finance and marketing across 23 markets. Writes on UK personal finance, tax, mortgages, insurance, energy, and investing. Sources: HMRC, FCA, Ofgem, BoE, ONS.

Stay ahead of your money

Free UK finance guides, rate changes and money-saving tips — straight to your inbox. No spam, unsubscribe anytime.

Read More

Get Kael Tripton in your Google feed

⭐ Add as Preferred Source on Google